- Lifecore Biomedical (NASDAQ: LFCR) to participate in the CDMO Live 2025 conference in Rotterdam.
- Jackie Klecker to chair a session on transforming quality management into a strategic driver.
- Conference scheduled for May 7-8, 2025, focusing on CDMO industry partnerships.
Lifecore Biomedical, Inc. (LFCR, Financial), a leading contract development and manufacturing organization (CDMO), will be participating in the CDMO Live 2025 conference, set to occur on May 7-8, 2025, in Rotterdam, Netherlands. This event is a prominent platform for partnerships within the biopharma outsourcing industry.
Jackie Klecker, Executive Vice President of Quality and Development Services at Lifecore, will lead a crucial discussion titled 'Quality as a Catalyst: Accelerating CDMO Success Through Quality Management' on Wednesday, May 7, 2025, at noon local time. This session will feature external quality leaders from the CDMO industry, examining strategies to transition quality management from a potential hindrance into a key driver of CDMO partnerships.
Klecker brings an extensive background with over 30 years of experience within the industry, particularly in quality, manufacturing, and development, including more than a decade of leadership in quality assurance at Lifecore.
Lifecore Biomedical, Inc. (LFCR, Financial) offers specialized development and manufacturing services for sterile injectable pharmaceutical products, and is renowned for its expertise as a manufacturer of premium, injectable-grade hyaluronic acid. With over 40 years of experience, the firm partners with both global and emerging biopharmaceutical and biotechnology companies across various therapeutic domains.
